<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
  <title>Statmint Publications</title>
  <meta name="description" content="Explore Statmint's weekly healthcare market reports, IPO analysis, FDA approvals and biotech stock updates." />
  <link rel="icon" href="statmint_logo.jpeg" type="image/jpeg" />

  <!-- Bootstrap -->
  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/css/bootstrap.min.css" rel="stylesheet" />

  <!-- AOS Animation -->
  <link href="https://unpkg.com/aos@2.3.4/dist/aos.css" rel="stylesheet" />

  <!-- Google Fonts -->
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet" />

  <style>
    body {
      background-color: #0d0d0d;
      color: #f1f1f1;
      font-family: 'Inter', sans-serif;
      line-height: 1.6;
    }

    .container {
      max-width: 900px;
    }

    h1 {
      font-size: 2.5rem;
      color: #00c9ff;
      text-shadow: 0 0 8px rgba(0, 201, 255, 0.3);
    }

    h2 {
      color: #00c9ff;
      margin-top: 2.5rem;
      margin-bottom: 1rem;
    }

    .publication {
      background: rgba(255, 255, 255, 0.03);
      border: 1px solid rgba(255, 255, 255, 0.05);
      border-radius: 12px;
      padding: 2rem;
      margin-bottom: 3rem;
      box-shadow: 0 0 10px rgba(0, 201, 255, 0.05);
      transition: all 0.3s ease;
    }

    .publication:hover {
      box-shadow: 0 0 20px rgba(0, 201, 255, 0.15);
    }

    footer {
      background-color: #111;
      padding: 1.5rem 1rem;
      text-align: center;
    }

    footer p {
      color: #999;
      font-size: 0.9rem;
    }
  </style>
</head>

<body>

<header class="text-center py-4 bg-black">
  <h1>ðŸ“˜ Statmint Publications</h1>
  <p class="text-muted">Weekly healthcare insights published every Sunday</p>
</header>

<main class="container py-5">

  <!-- August 18, 2025 Issue -->
  <div class="publication" data-aos="fade-up">
    <h2>Statmint Weekly â€” August 18, 2025</h2>
    <p class="text-muted">Published Sunday, August 18, 2025</p>

    <h3>ðŸ§ª FDA Approval Highlights</h3>
    <ul>
      <li><strong>Veradineâ€™s VX-105</strong> received accelerated approval for treatment-resistant lung cancer.</li>
      <li><strong>Emergex Biotech</strong> granted EUA for mosquito-borne virus vaccine in South America.</li>
    </ul>

    <h3>ðŸ“ˆ IPO Watch</h3>
    <ul>
      <li><strong>Oncova Therapeutics (ONCV)</strong> raised $112M, closing +9% on first day.</li>
      <li><strong>Biogenix (BGNX)</strong> filed IPO targeting $150M for rare liver disease platform.</li>
    </ul>

    <h3>ðŸ”¬ Stocks to Watch</h3>
    <ul>
      <li><strong>Neurovia (NRVA)</strong> â€” Phase 3 Alzheimerâ€™s trial readout expected Thursday.</li>
      <li><strong>Genexia (GEX)</strong> â€” Up 18% on strong preclinical data.</li>
    </ul>

    <h3>ðŸ“° Healthcare Market News</h3>
    <ul>
      <li>Senate drug pricing hearing set for Aug 22.</li>
      <li>Moderna announces European vaccine partnership.</li>
      <li>Biotech ETF (XBI) rose 2.6% this week on small-cap recovery.</li>
    </ul>

    <blockquote class="blockquote text-info">
      "14 biotech IPOs have launched since July 1, raising a combined $1.4B â€” the strongest 6-week stretch since early 2022."
    </blockquote>

    <p><strong>Insight:</strong> Investor sentiment is returning to CNS and oncology biotech, with IPOs regaining momentum.</p>
  </div>

  <!-- August 17, 2025 Issue -->
  <div class="publication" data-aos="fade-up">
    <h2>Statmint Weekly â€” August 17, 2025</h2>
    <p class="text-muted">Published Sunday, August 17, 2025</p>

    <h3>ðŸ§ª FDA Approval Highlights</h3>
    <ul>
      <li><strong>BioNovaâ€™s BLV-301</strong> approved for rare leukemia â€” $600M peak sales expected.</li>
      <li><strong>NeuroCura NC-12</strong> granted Fast Track for Alzheimerâ€™s treatment.</li>
    </ul>

    <h3>ðŸ“ˆ IPO Tracker</h3>
    <ul>
      <li><strong>Genovex (GNVX)</strong> raised $88M, opening +14% over listing.</li>
      <li><strong>HelixBio</strong> filed confidentially for Q4 IPO.</li>
    </ul>

    <h3>ðŸ”¬ Clinical Trials to Watch</h3>
    <ul>
      <li>Cardiomaxâ€™s <strong>CMX-101</strong> Phase 3 heart failure results expected Friday.</li>
      <li><strong>Dermovita DV-09</strong> trial paused over safety concerns.</li>
    </ul>

    <h3>ðŸ“Š Market Movers</h3>
    <ul>
      <li><strong>Argenix</strong> +18% after positive ARX-12 combo data.</li>
      <li><strong>TravaGen</strong> -11% after weak Q2 earnings.</li>
    </ul>

    <blockquote class="blockquote text-info">
      "8 of the last 10 FDA approvals have targeted rare or orphan conditions."
    </blockquote>

    <p><strong>Insight:</strong> IPO activity is rebounding, with Genovexâ€™s debut signaling renewed interest in early oncology assets.</p>
  </div>

</main>

<footer>
  <p>&copy; 2025 Statmint. All rights reserved.</p>
</footer>

<!-- Scripts -->
<script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.0/dist/js/bootstrap.bundle.min.js"></script>
<script src="https://unpkg.com/aos@2.3.4/dist/aos.js"></script>
<script>
  AOS.init({ duration: 1000, once: true });
</script>

</body>
</html>
